EDITORIAL SECTION
-
STRATEGY
Smarter Pharma
Quality management systems QMS are the backbone of pharmaceutical manufacturing ensuring safe products
-
RESEARCH DEVELOPMENT
Cytiva Laboratory capsule filters
Our singleuse selfcontained filtration solution
-
CLINICAL TRIALS
Why Clinical Trials Need Digital Endpoints
According Citeline the average success rate for bringing a Phase candidate to market has dropped to an alltime low of just
-
MANUFACTURING
Ensuring Quality and Compliance in Biopharma
Ensuring quality and regulatory compliance in the biopharmaceutical industry is critical to safeguarding product safety and efficacy
-
Information Technology
The Cost of Bad Data
Modern pharmaceutical research generates an unprecedented volume of information Data from genomic sequencing
-
Biopharma
Reimagining Global Biomanufacturing Capacity with Continuous and Modular Systems
Biotechnology is fueling the ongoing expansion of the global market for a broad array of goods
-
EXPERT Talk
What Changes at Scale, and How Do You Know?
A pharmaceutical process that performs reliably on a few grams of material can behave very differently at pilot or commercial scale The temperature setpoint that worked on the bench the mixing time that delivered a uniform blend the feed rate that kept a reaction on track none of these is guaranteed to mean the same thing in larger equipment When that difference goes...
Advisory Board
KNOWLEDGE BANK
-
Articles
Advertise Smarter with the 2025 Pharma Focus Europe Media Pack
The internet has forever changed the healthcare industry and it is no longer whether to advertise but how to advertise better in the changing digital world Following the shift of pharma marketing to precision personalization and performance Pharma Focus Europe Media Pack is precisely your prescription to be the best in terms of competing in the European market
Breaking Down Barriers: Advancements in Biodegradable Drug Delivery
In todays world where sustainability is a top priority breaking down barriers to a greener future is crucial One area where advancements are being made is in the field of biodegradable drug delivery
Rethinking Make-or-Buy: Strategic Manufacturing Decisions in Pharma
Few strategic decisions in pharmaceutical operations carry as much longterm consequence as the choice of what to make and what to buy and few are revisited as rarely Network footprints agreed a decade ago partners selected during a capacity crunch technology transfers completed under launch pressure these choices harden into architecture They stop looking like decisions and start looking like the...
The Rise of Continuous Clinical Trials: Redefining Drug Development
The conventional clinical trial is a disposable asset A sponsor writes a protocol for a single compound activates a network of sites recruits a control group reads out and then dismantles everything it has built When the next candidate arrives often in the same disease often at the same hospitals
Unveiling Hope: Progress and Challenges in Rare Disease Drug Development
Rare diseases often referred to as orphan diseases affect a small percentage of the population Despite their rarity these diseases collectively impact millions of people worldwide The development of drugs
How Digitalization Improves Pharma Manufacturing and Compliance
The pharmaceutical industry has been at a crossroads where the digitalization process is transforming the way drugs are developed manufactured and monitored Pharmaceutical companies are capitalizing on the power of digitalization in pharmaceutical production to maximize production improve traceability and regulatory compliance due to the tough regulatory requirements and the demand for absolute pr...
-
Techno Trends
Alume Biosciences Secures FDA Breakthrough Therapy Designation for Bevonescein
Alume Biosciences has received Breakthrough Therapy Designation BTD from the US Food and Drug Administration FDA for bevonescein an investigational fluorescent drug being developed to support realtime nerve visualisation during head and neck surgery in adults Bevonescein is an intravenous fluorescent peptidedye conjugate that binds to nerve tissue
-
Projects
SK pharmteco Plans More Than US$200 Million Investment in Small Molecule and Peptide Manufacturing
SK pharmteco is planning a fiveyear investment of more than US million to expand and modernise its pharmaceutical development and manufacturing operations in the United States The programme will strengthen capabilities for small molecules and peptides while supporting a more
-
Research Insights
A drug repurposing screen reveals dopamine signaling as a candidate therapeutic pathway for PIGA-CDG
PIGACDG is a congenital disorder of glycosylation caused by pathogenic partial lossoffunction variants in the PIGA gene PIGA encodes an enzyme responsible for the catalytic transfer of Nacetylglucosamine
-
whitepaper
Post-Translational Modifications in Drug Discovery: From Molecular Regulation to Clinical Impact
For decades the central dogma of molecular biology has anchored our understanding of cellular function DNA to RNA to protein But this linear view is incomplete A growing body of evidence shows that much of biologys
TOP ARTICLES
-
1
Breaking Down Barriers: Advancements in Biodegradable Drug Delivery
Kate Williamson
This article discusses the benefits and advancements in biodegradable drug delivery systems, highlighting their role in improving patient outcomes and reducing environmental impact. It covers the adva...
-
2
Rethinking Make-or-Buy: Strategic Manufacturing Decisions in Pharma
Lakshmi
For three decades, pharmaceutical manufacturers treated outsourcing as the default answer to capacity, cost and speed pressures. Supply disruptions, modality complexity and regulatory scrutiny have si...
-
3
The Rise of Continuous Clinical Trials: Redefining Drug Development
Lakshmi
Clinical development is shifting from discrete, asset-anchored studies towards continuous platforms in which therapies enter and leave a standing trial under a single master protocol. Shared controls...
-
4
Unveiling Hope: Progress and Challenges in Rare Disease Drug Development
Kate Williamson
Rare disease drug development has progressed significantly due to advancements in genomics and molecular biology, offering new hope to millions. Despite challenges like limited patient populations and...
-
5
How Digitalization Improves Pharma Manufacturing and Compliance
Kate Williamson
Digitalization of pharmaceutical production transforms the production, quality, and compliance by automation, data integration, and smart technologies. Using Pharma 4.0 principles, the companies obtai...
press releases Read more...
Erasca Enters into Clinical Collaboration with Bristol Myers Squibb to Evaluate ERAS-0015 in Clinical Study with Navlimetostat
Erasca Inc Nasdaq ERAS a clinicalstage precision oncology company singularly focused on discovering developing and commercializing therapies for patients with RASMAPK pathwaydriven cancers today announced a clinical
Verismo Therapeutics Licenses In Vivo CAR T Engineering Technology to Extend Its Novel Multi-Chain KIR-CAR Platform
Verismo Therapeutics a clinicalstage CAR T cell therapy company pioneering a novel multichain KIRCAR platform technology announced today that the company licensed the PACKIT technology enabling in vivo engineering of KIRCAR
22nd Edition Project Portfolio and Resource Management Excellence for Pharma and BioTech
Pharma organisations are still in a transition process from traditional model centered on blockbuster to more collaborative global ones In order to address the main challenge of RD productivity PPM professional serve as a link between operational teams
Cancer Research UK and Dewpoint Therapeutics partner to advance potential first-in-class MYC condensate modulator into clinical development
Cancer Research UK and Dewpoint Therapeutics today announced a collaboration and licence agreement to advance DPTX a potential firstinclass small molecule modulator of MYC condensates into clinical development
Events Read more...
24 - 27
Nov 2026Pharmtech & Ingredients 2026
Crocus Expo, Pavilion 2, Mosco...
24 - 25
Nov 2026BioPharma Deals Conference 2026
Science Congress Center, Munic...
25 - 25
Nov 2026What’s Next for Pharma Marketing in 2027
Landesmuseum Zürich, Zurich, S...
26 - 28
Nov 2026One Health Conference 2026
Thapar Institute of Engineerin...
01 - 03
Dec 2026Pharmaceutical Launch Excellence Summit
Novotel Amsterdam City, Nether...
01 - 03
Dec 202610th Antifibrotic Drug Development
Boston, MA at the Hotel Common...
02 - 04
Dec 2026Genome Informatics 2026
Wellcome Genome Campus, UK
03 - 04
Dec 2026Pharmacy and Pharmaceutical Conference
Madrid, Spain
LATEST NEWS Read more...
CAI Enters Agreement with PQE Group to Expand Global Life Sciences Services
CAI a professional services firm specialising in operational readiness and excellence for life sciences and other critical industries has entered into a definitive agreement with PQE Group a global consulting firm focused on quality compliance
Erasca Partners with Bristol Myers Squibb to Study ERAS-0015 Combination Therapy for Pancreatic Cancer
Erasca Inc a clinicalstage precision oncology company focused on developing treatments for cancers driven by the RASMAPK signalling pathway has entered into a clinical trial collaboration and supply agreement with Bristol Myers Squibb BMS
Libtayo Receives EU Approval for Extended Dosing and Shorter Infusion Times Across Six Cancer Indications
Regeneron Pharmaceuticals has received European Commission EC approval for an alternative dosing schedule for Libtayo cemiplimab across all six of its approved indications for skin lung and cervical cancers in the European Union EU
FDA approves Roche’s Wilserdly for ER-positive, ESR1-mutated advanced breast cancer
Roche has received approval from the US Food and Drug Administration FDA for Wilserdly giredestrant in combination with everolimus to treat adults with oestrogen receptor ERpositive human epidermal growth factor receptor HERnegative ESRmutated locally advanced or metastatic breast cancer
European Commission approves Revolution Medicines’ RASONQUE for metastatic pancreatic cancer
Revolution Medicines has received European Commission EC approval for RASONQUE daraxonrasib to treat adults with metastatic pancreatic adenocarcinoma who have received at least one previous systemic therapy The medicine is taken once daily as an oral tablet and is approved for patients with or witho...
Immuneering and Astellas to Evaluate Combination Treatments for CLDN18.2-Expressing Pancreatic Cancer
Immuneering Corporation Nasdaq IMRX has entered into a clinical trial collaboration and supply agreement with Astellas Pharma Global Development Inc a subsidiary of Astellas Pharma Inc TSE to evaluate combination treatments for patients with pancreatic cancer whose tumours express CLDN








